Agios Pharmaceuticals said Monday that its drug called mitapivat reduced the need for blood transfusions in patients with a severe form of beta-thalassemia,...
Read More
STAT+: Agios drug reduces blood transfusions in patients with beta-thalassemia, study shows
Agios Pharmaceuticals said Monday that its drug called mitapivat reduced the need for blood transfusions in patients with a severe form of beta-thalassemia, an inherited blood disorder. The results achieved the primary goal of a placebo-controlled Phase 3 clinical trial, and
Constitutional Nobody
June 3, 2024
